SEARCH

SEARCH BY CITATION

References

  • 1
    Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979; 16: 10116.
  • 2
    Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, Bachinger HP, Pace JM, Schwarze U, Byers PH, Weis M, Fernandes RJ, Eyre DR, Yao Z, Boyce BF, Lee B. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006; 127: 291304.
  • 3
    Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makaareva E, Kuznestova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007; 39: 35965.
  • 4
    Van Dijk FS, Nesbitt IM, Zwikstra EJ, Nikkels PG, Piersman SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MH, Elting MW, Verbeke JI, Wijnaendts LC, Shaw NJ, Högler W, McKeown C, Sistermans EA, Dalton A, Meijers-Heijboer H, Pais G. PPIB mutations cause severe recessive osteogenesis imperfecta. Am J Hum Genet. 2009; 85: 5217.
  • 5
    Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, Alikasifoglu M, Tuncbilek E, Orhan D, Bakar FT, Zabel B, Superti-Furga A, Bruckner-Tuderman L, Curry CJ, Pyott S, Byers PH, Eyre DR, Baldridge D, Lee B, Merril AE, Davis EC, Cohn DH, Akarsu N, Krakow D. Mutations in the gene encoding the RER protein FKBP65 cause autosomal recessive osteogenesis imperfecta. Am J Hum Genet. 2010; 86: 5519.
  • 6
    Christiansen HE, Schwarze U, Pyott SM, Al Swaid A, Al Balwi M, Alrasheed S, Pepin MG, Weis MA, Eyre DR, Byers PH. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010; 86: 38998.
  • 7
    Lapunzina P, Aglan M, Temtamy S, Caparrós-Martin JA, Valencia M, Letón R, Martínez-Glez V, Elhossini R, Amr K, Vilaboa N, Ruiz-Perez VL. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet. 2010; 87: 1104.
  • 8
    Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002; 17: 308.
  • 9
    Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrabach M, Koerber F, Zimmermann K, de Vries P, Wirth B, Schoenau E, Wollnik B, Veltman JA, Hoischen A, Netzer C. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal recessive osteogenesis imperfecta. Am J Hum Genet. 2011; 88: 36271.
  • 10
    Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S, Travers R, Glorieux FH, Lee B. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res. 2011; 26: 2798803.
  • 11
    Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM. Normative data for iliac bone histomorphometry in growing children. Bone. 2000; 26: 1039.
  • 12
    Quan GMY, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PFM. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif Tissue Int. 2005; 76: 14653.
  • 13
    Broadhead ML, Akiyama T, Choong PFM, Dass CR. The pathophysiological role of PEDF in bone diseases. Curr Mol Med. 2010; 10: 26778.
  • 14
    Meyer C, Notari L, Becerra SP. Mapping the type I collagen-binding site on pigment epithelium-derived factor. J Biol Chem. 2002; 277: 454007.
  • 15
    Akiyama T, Dass CR, Shinoda Y, Kavano H, Tanaka S, Choong PFM. PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Res Commun. 2010; 391: 78994.
  • 16
    Takenaka K, Yamagishi S, Jinnouchi Y, Nakamura K, Imaizumi T. Pigment epithelium-derived factor (PEDF)–induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci. 2005; 77: 323141.
  • 17
    Kawaguchi T, Yamagishi SI, Sata M. Structure-function relationship of PEDF. Curr Mol Med. 2010; 10: 30211.
  • 18
    Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007; 40: 63844.
  • 19
    Manalo KB, Choong PF, Becerra SP, Dass CR. Pigment epithelium-derived factor as an anticancer drug and new treatment methods following the discovery of its receptors: a patent perspective. Expert Opin Ther Pat. 2011; 21: 12130.